• Topotecan-Vincristine-Doxorubicin in stage 4 high-Risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: A SIOPEN study.

      Amoroso, L; Erminio, G; Makin, Guy; Pearson, A; Brock, P; Valteau-Couanet, D; Castel, V; Pasquet, M; Laureys, G; Thomas, C; et al. (2018-01)
      Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response (CR) or partial response (PR) with ≤ three abnormal skeletal areas on iodine 123-metaiodobenzylguanidine ([123I]mIBG) scintigraphy and no bone marrow disease proceed to high dose therapy (HDT). In this study, topotecan-vincristine-doxorubicin (TVD) was evaluated in patients failing to achieve these criteria, with the aim of improving the metastatic response rate.